A large number of patients initially respond to androgen/AR-directed therapies, however over time patients inevitably relapse as tumor cells transform and become resistant to treatment, termed castrate-resistant prostate cancer (CRPC) [4]. The gene discussed is AR; the disease is neoplasm.